ASND — Ascendis Pharma A/S Share News
0.000.00%
Last trade - 00:00- $15.00bn
- $14.59bn
- €720.13m
Ascendis Pharma A/S expected to post a loss of €1.74 a share - Earnings Preview
Ascendis Pharma A/S expected to post a loss of €1.73 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Array Technologies, Hess, Lennar
Ascendis Pharma A/S reports results for the quarter ended in June 30 - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €1.42 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Agree Realty, Global Payments, Snowflake
Ascendis Pharma's hormone disorder therapy gets US approval (updated)
FDA extends review of Ascendis Pharma's hormone disorder therapy (updated)
FDA extends review of Ascendis Pharma's hormone disorder therapy
Ascendis Pharma A/S reports results for the quarter ended in March - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €1.50 a share - Earnings Preview
Ascendis Pharma A/S expected to post a loss of €1.50 a share - Earnings Preview
Ascendis Pharma A/S reports results for the quarter ended in December - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €2.14 a share - Earnings Preview
Ascendis Pharma A/S expected to post a loss of €2.38 a share - Earnings Preview
Ascendis Pharma A/S expected to post a loss of €2.42 a share - Earnings Preview
Ascendis Pharma A/S reports results for the quarter ended in June - Earnings Summary
Ascendis Pharma A/S expected to post a loss of €2.59 a share - Earnings Preview
Ascendis Pharma A/S expected to post a loss of €2.59 a share - Earnings Preview